Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer
Status:
Not yet recruiting
Trial end date:
2022-08-20
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, double-dummy, parallel-group,
active-controlled Phase III clinical study to evaluate the efficacy and safety of LXI-15028
50mg comparing with Lansoprazole 30 mg after the treatment of duodenal ulcer in Chinese
patients for up to 6 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.